Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

Prior treatment

• Patients who have undergone major organ surgery within the last 6 weeks;
• Patients whom the investigator deems unsuitable for this clinical trial (e.g., poor compliance, drug abuse, etc.).

Other illness

• Patients who are allergic to the study medication or have contraindications to it;
• Patients with active infections;
• Patients with mental disorders or other conditions that prevent obtaining informed consent, or who are unable to cooperate with the treatment and examination procedures;

Lab values

• Abnormal liver function, with total bilirubin \> 1.5 times the upper limit of normal, ALT/AST \> 2.5 times the upper limit of normal, or liver-infiltrated patients with ALT/AST \> 5 times the upper limit of normal; abnormal renal function, with serum creatinine \> 1.5 times the upper limit of normal;

Other

• Pregnant or breastfeeding women;
• Patients with long-term smoking or alcohol abuse that could affect the evaluation of trial results;

• Voluntary participation in the clinical study; the subject or legal guardian fully understands and is informed about the study and has signed the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures;
• Age between 60-75 years at the time of screening, with no gender restrictions;
• Patients are newly diagnosed with AML, and the diagnosis conforms to the standards of the Chinese Medical Association 2021 edition;
• No severe allergic constitution;
• Liver function: ALT and AST \<= 2.5 times the upper limit of normal values, bilirubin \<= 2 times the upper limit of normal values;
• Renal function: creatinine \<= upper limit of normal values;
• No uncontrollable infections or severe mental illnesses;
• Performance status score is 0-3 (ECOG), with an expected survival of at least 4 months.